ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment
ProPhase Labs (NASDAQ:PRPH) has secured U.S. Patent No. 12379378-B2 for its biomarker-based systems and methods to assess progression risk in Barrett's esophagus and esophageal adenocarcinoma. The patent follows the successful validation of the company's 叠贰-厂尘补谤迟鈩� molecular diagnostic test, which achieved a 95% technical success rate in detecting the patented biomarker panel.
The 叠贰-厂尘补谤迟鈩� test platform demonstrates compatibility with both brush and forceps biopsies, enhancing early detection capabilities. The patent, filed in December 2023, covers methods for detecting key biomarkers including ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and GPI. The technology also enables novel treatment approaches and supports more accurate identification of high-risk patients.
ProPhase Labs (NASDAQ:PRPH) ha ottenuto il brevetto statunitense n. 12379378-B2 per i suoi sistemi e metodi basati su biomarcatori volti a valutare il rischio di progressione nell'esofago di Barrett e nell'adenocarcinoma esofageo. Il brevetto segue la convalida del test diagnostico molecolare 叠贰-厂尘补谤迟鈩� dell'azienda, che ha registrato un 95% di successo tecnico nel rilevare il pannello di biomarcatori brevettato.
La piattaforma 叠贰-厂尘补谤迟鈩� 猫 compatibile sia con campionamenti tramite spazzola sia con biopsie con pinze, migliorando le capacit脿 di rilevamento precoce. Il brevetto, depositato nel dicembre 2023, copre metodi per identificare biomarcatori chiave quali ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P e GPI. La tecnologia favorisce inoltre nuovi approcci terapeutici e una pi霉 accurata identificazione dei pazienti ad alto rischio.
ProPhase Labs (NASDAQ:PRPH) ha obtenido la patente estadounidense n.潞 12379378-B2 para sus sistemas y m茅todos basados en biomarcadores destinados a evaluar el riesgo de progresi贸n en el es贸fago de Barrett y el adenocarcinoma esof谩gico. La patente llega tras la validaci贸n del test diagn贸stico molecular 叠贰-厂尘补谤迟鈩� de la compa帽铆a, que alcanz贸 un 95% de 茅xito t茅cnico en la detecci贸n del panel de biomarcadores patentado.
La plataforma 叠贰-厂尘补谤迟鈩� es compatible tanto con cepillado como con biopsias con pinza, mejorando la capacidad de detecci贸n temprana. La patente, presentada en diciembre de 2023, cubre m茅todos para detectar biomarcadores clave como ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P y GPI. La tecnolog铆a tambi茅n posibilita nuevos enfoques terap茅uticos y una identificaci贸n m谩s precisa de los pacientes de alto riesgo.
ProPhase Labs (NASDAQ:PRPH)電� 氚旊牄 鞁濍弰 氚� 鞁濍弰 靹犾晹鞚� 歆勴枆 鞙勴棙鞚� 韽夑皜頃橁赴 鞙勴暅 氚旍澊鞓る旎� 旮半皹 鞁滌姢韰� 氚� 氚╇矔鞐� 雽�頃� 氙戈淡 韸鬼棃 氩堩樃 12379378-B2毳� 須嶋摑頄堨姷雼堧嫟. 鞚� 韸鬼棃電� 須岇偓鞚� 攵勳瀽 歆勲嫧 瓴�靷� 叠贰-厂尘补谤迟鈩�臧� 頃措嫻 韸鬼棃 氚旍澊鞓る旎� 韺剱鞚� 韮愳頃橂姅 雿� 鞛堨柎 95%鞚� 旮办垹鞝� 靹标车毳�鞚� 雼劚頃� 瓴�歃� 瓴瓣臣鞐� 霐半ジ 瓴冹瀰雼堧嫟.
叠贰-厂尘补谤迟鈩� 瓴�靷� 頂岆灚韽检潃 敫岆煬鞁� 氚� 韽厜(瓴胳瀽) 靸濌瞼 氇憪鞕� 順疙櫂霅橃柎 臁瓣赴 氚滉铂 電ル牓鞚� 頄レ儊鞁滍偟雼堧嫟. 2023雲� 12鞗� 於滌洂霅� 鞚� 韸鬼棃電� ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P 氚� GPI 霌� 欤检殧 氚旍澊鞓る旎� 瓴�於� 氚╇矔鞚� 韽暔頃╇媹雼�. 霕愴暅 鞚� 旮办垹鞚� 靸堧鞖� 旃橂 鞝戧芳鞚� 臧�電ロ晿瓴� 頃橁碃 瓿犾渼項� 頇橃瀽 鞁濍硠鞚� 氤措嫟 鞝曧檿頃橁矊 歆�鞗愴暕雼堧嫟.
ProPhase Labs (NASDAQ:PRPH) a obtenu le brevet am茅ricain n掳 12379378-B2 pour ses syst猫mes et m茅thodes bas茅s sur des biomarqueurs visant 脿 茅valuer le risque de progression dans l'艙sophage de Barrett et l'ad茅nocarcinome 艙sophagien. Ce brevet fait suite 脿 la validation r茅ussie du test diagnostique mol茅culaire 叠贰-厂尘补谤迟鈩� de la soci茅t茅, qui a atteint un taux de r茅ussite technique de 95% pour la d茅tection du panel de biomarqueurs brevet茅.
La plateforme 叠贰-厂尘补谤迟鈩� est compatible 脿 la fois avec les pr茅l猫vements par brosse et par pince, renfor莽ant les capacit茅s de d茅tection pr茅coce. D茅pos茅 en d茅cembre 2023, le brevet couvre des m茅thodes de d茅tection de biomarqueurs cl茅s tels que ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P et GPI. La technologie ouvre 茅galement la voie 脿 de nouvelles approches th茅rapeutiques et permet d'identifier plus pr茅cis茅ment les patients 脿 haut risque.
ProPhase Labs (NASDAQ:PRPH) hat das US-Patent Nr. 12379378-B2 f眉r seine biomarkerbasierten Systeme und Methoden zur Bewertung des Progressionsrisikos beim Barrett-脰sophagus und beim 脰sophagusadenokarzinom erhalten. Das Patent folgt auf die erfolgreiche Validierung des molekularen Diagnosetests 叠贰-厂尘补谤迟鈩� des Unternehmens, der eine 95%ige technische Erfolgsquote beim Nachweis des patentierten Biomarker-Panels erreichte.
Die 叠贰-厂尘补谤迟鈩�-Plattform ist sowohl mit B眉rsten- als auch mit Zangenbiopsien kompatibel und verbessert damit die M枚glichkeiten der Fr眉herkennung. Das im Dezember 2023 angemeldete Patent umfasst Methoden zum Nachweis zentraler Biomarker wie ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P und GPI. Die Technologie erm枚glicht zudem neue Behandlungsans盲tze und unterst眉tzt eine genauere Identifikation von Hochrisiko-Patienten.
- None.
- None.
Insights
ProPhase's patent approval strengthens its position in esophageal cancer diagnostics following strong BE-Smart test validation, enhancing commercialization potential.
ProPhase Labs has secured a critical intellectual property milestone with the issuance of U.S. Patent No. 12379378-B2, which protects their biomarker-based systems for assessing progression risk in Barrett's esophagus and esophageal adenocarcinoma. This patent approval comes at a strategically valuable time, following the company's recent validation of their 叠贰-厂尘补谤迟鈩� diagnostic test that demonstrated an impressive
The patent specifically covers detection methods for key biomarkers including ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and GPI 鈥� forming the scientific foundation of the 叠贰-厂尘补谤迟鈩� platform. What makes this particularly valuable is the test's validated compatibility with both brush cytology and forceps biopsies, offering flexible sampling approaches that can enhance early detection capabilities.
This dual-compatibility approach is technically significant as it addresses different clinical needs: brush biopsies provide broader epithelial cell sampling while forceps biopsies enable targeted tissue examination. This versatility should facilitate wider clinical adoption and potentially easier integration into existing gastroenterology workflows.
The comprehensive scope of the patent, which includes not only diagnostic applications but also potential treatment approaches (inhibiting cancer cell proliferation/migration and enhancing tumor susceptibility to cytotoxic therapies), creates multiple commercialization avenues. By securing this intellectual property protection approximately 20 months after the December 2023 filing date, ProPhase has established a competitive barrier in the esophageal diagnostics market that will likely strengthen their market position as they move toward commercialization.
U.S. Patent No. 12379378-B2 protects biomarker-driven systems and methods to assess progression risk in Barrett鈥檚 esophagus and esophageal adenocarcinoma; issuance follows the successful BE-Smart鈩� test validation (>
UNIONDALE, NY, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (the 鈥淐ompany鈥� or 鈥淧roPhase鈥�) today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12379378-B2 for the Company鈥檚 biomarker-based systems and methods to assess progression risk in Barrett鈥檚 esophagus and esophageal adenocarcinoma. The patent issuance closely follows ProPhase鈥檚 June 17, 2025 announcement validating its BE-Smart鈩� molecular diagnostic, which achieved greater than a
Brush biopsies can capture a broader, more representative epithelial cell population, while forceps biopsies provide targeted tissue sampling; by working with both, BE鈥慡mart is designed to enhance early detection and risk stratification in patients with GERD, Barrett鈥檚 esophagus, and other distal esophageal disorders.
U.S. Patent No. 12379378-B2, originally filed on December 7, 2023, was developed by inventors Joe Abdo, Sumeet K. Mittal, and Devendra K. Agrawal. The patent covers systems and methods for assessing the risk of Barrett's esophagus pathogenesis and esophageal adenocarcinoma progression by detecting key biomarkers such as ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and GPI, and it underpins the Company鈥檚 BE-Smart鈩� test platform.
Issuance of this patent underscores the strong scientific foundation and clinical relevance of ProPhase Labs鈥� technology. Beyond risk assessment, these patented methods also enable novel treatment approaches - including inhibiting cancer cell proliferation and migration and enhancing tumor susceptibility to cytotoxic therapies - and support more accurate, earlier identification of patients at elevated risk.
鈥淭his achievement, coming on the heels of our BE-Smart鈩� validation demonstrating greater than a
About ProPhase Labs, Inc.
ProPhase Labs Inc. (Nasdaq: PRPH) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We deliver industry-leading Whole Genome Sequencing solutions, develop groundbreaking diagnostics - including BE-Smart鈩�, a potentially life-saving test for the early detection of esophageal cancer - and operate a world-class direct-to-consumer platform for cutting-edge OTC dietary supplements. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach that we believe positions ProPhase for long-term value creation. For more information, please visit .
Forward-Looking Statements
Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our expectations regarding the future revenue growth potential of each of our subsidiaries, our expected timeline for commercializing our BE-Smart Esophageal Cancer Test, our expectations regarding future liquidity events, the success of our efforts to collect accounts receivables and anticipated timeline for any payments relating thereto, and our ability to successfully transition into a consumer products company. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.
No Offer or Solicitation
The information contained in this press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. The statements made herein reflect the Company鈥檚 current views with respect to potential business opportunities and are based on currently available information, assumptions, and expectations. These statements are not guarantees of future performance or outcomes and are subject to risks and uncertainties. Comparisons to other companies or transactions, if any, are provided solely for illustrative purposes and do not imply any specific valuation or outcome. No assurance can be given that any transaction will be pursued or consummated.
Contacts
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman:
Tel.: (416) 644-2020 or (212) 812-7680
